Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.

Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV.

Mayo Clin Proc. 2007 Oct;82(10):1179-84.

PMID:
17908524
2.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

3.

Integrating novel therapies in the transplant paradigm.

Harousseau JL.

Cancer J. 2009 Nov-Dec;15(6):479-84. doi: 10.1097/PPO.0b013e3181c51ca3. Review.

PMID:
20010167
4.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
5.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
6.

How lenalidomide is changing the treatment of patients with multiple myeloma.

Dimopoulos MA, Terpos E, Niesvizky R.

Crit Rev Oncol Hematol. 2013 Oct;88 Suppl 1:S23-35. doi: 10.1016/j.critrevonc.2013.05.013. Epub 2013 Jun 28. Review.

PMID:
23816163
7.

Lenalidomide in the treatment of multiple myeloma: a review.

Armoiry X, Aulagner G, Facon T.

J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x. Review.

PMID:
18452408
8.

Lenalidomide in multiple myeloma.

Kim Y, Schmidt-Wolf IG.

Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407. Epub 2015 Apr 5. Review.

PMID:
25843431
9.

Thalidomide in multiple myeloma: past, present and future.

Harousseau JL.

Future Oncol. 2006 Oct;2(5):577-89. Review.

PMID:
17026450
10.

[Lenalidomide maintenance therapy in patients with multiple myeloma].

Roziaková L, Mistrík M.

Klin Onkol. 2013;26(3):186-90. Review. Czech.

PMID:
23763321
11.

Initial treatment of transplant-ineligible patients in multiple myeloma.

Mateos MV, Leleu X, Palumbo A, San Miguel JF.

Expert Rev Hematol. 2014 Feb;7(1):67-77. doi: 10.1586/17474086.2014.864230. Epub 2013 Nov 28. Review.

PMID:
24308500
12.

Advances in the management of asymptomatic myeloma.

Mateos MV.

Curr Opin Oncol. 2014 Nov;26(6):670-6. doi: 10.1097/CCO.0000000000000121. Review.

PMID:
25210868
13.

New approaches to smoldering myeloma.

Mateos MV, San Miguel JF.

Curr Hematol Malig Rep. 2013 Dec;8(4):270-6. doi: 10.1007/s11899-013-0174-1. Review.

PMID:
23975678
14.

Preclinical rationale, mechanisms of action, and clinical activity of anthracyclines in myeloma.

Hussein MA.

Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S145-9. Review.

PMID:
17562252
15.

Management of asymptomatic myeloma patients.

Mateos MV.

Expert Rev Hematol. 2015 Feb;8(1):19-27. doi: 10.1586/17474086.2015.978852. Epub 2014 Nov 3. Review.

PMID:
25363073
16.

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Landgren O, Iskander K.

J Intern Med. 2017 Apr;281(4):365-382. doi: 10.1111/joim.12590. Epub 2017 Feb 16. Review.

PMID:
28205262

Supplemental Content

Support Center